Opportunity ID: 353797

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-AI-24-025
Funding Opportunity Title: Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.855 — Allergy and Infectious Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 25, 2024
Last Updated Date: Apr 25, 2024
Original Closing Date for Applications: Oct 09, 2024
Current Closing Date for Applications: Oct 09, 2024
Archive Date: Nov 14, 2024
Estimated Total Program Funding:
Award Ceiling: $750,000
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Special district governments
For profit organizations other than small businesses
Private institutions of higher education
Small businesses
Native American tribal governments (Federally recognized)
City or township governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
State governments
Independent school districts
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Notice of Funding Opportunity (NOFO) is to support basic and applied research to understand and improve durable immune responses to candidate HIV vaccines.
Link to Additional Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-025.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH Grants Information
grantsinfo@nih.gov
Email:grantsinfo@nih.gov

Version History

Version Modification Description Updated Date

Folder 353797 Full Announcement-RFA-AI-24-025 -> RFA-AI-24-025-Full-Announcement.pdf

Packages

Agency Contact Information: NIH Grants Information
grantsinfo@nih.gov
Email: grantsinfo@nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-H Use for due dates on or after January 25, 2023 PKG00286080 Sep 09, 2024 Oct 09, 2024 View

Package 1

Mandatory forms

353797 RR_SF424_5_0-5.0.pdf

353797 PHS398_CoverPageSupplement_5_0-5.0.pdf

353797 RR_OtherProjectInfo_1_4-1.4.pdf

353797 PerformanceSite_4_0-4.0.pdf

353797 RR_KeyPersonExpanded_4_0-4.0.pdf

353797 PHS398_ResearchPlan_5_0-5.0.pdf

353797 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

353797 RR_Budget_3_0-3.0.pdf

353797 RR_SubawardBudget30_3_0-3.0.pdf

353797 PHS398_ModularBudget_1_2-1.2.pdf

353797 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-12T12:56:30-05:00

Share This Post, Choose Your Platform!

About the Author: